Deltex Medical Group PLC Exercise of Options (5395B)
April 04 2017 - 6:51AM
UK Regulatory
TIDMDEMG
RNS Number : 5395B
Deltex Medical Group PLC
04 April 2017
4 April 2017
Deltex Medical Group plc
("Deltex Medical" or "the Company")
Exercise of Options
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM") announces that it has issued
110,000 new Ordinary Shares of 1 pence each in the capital of the
Company ("Ordinary Shares") in connection with the exercise of
options by a former employee granted under the Company's 2003 share
option scheme. The options had an exercise price of 1 pence per
share and the notice of exercise was received on 31 March 2017.
Application has been made for the 110,000 new Ordinary Shares to
be admitted to trading on AIM ("Admission"), and dealings are
expected to commence on 10 April 2017. The new Ordinary Shares will
rank pari passu with the Company's existing Ordinary Shares.
The total number of Ordinary Shares in issue following Admission
will be 296,741,733. The Company does not hold any shares in
treasury. Accordingly, the figure of 296,741,733 may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in the Company under the FCA's
Disclosure Guidance and Transparency Rules.
For further information, please contact:-
Deltex Medical Group 01243 774 837
plc investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief
Executive
Jonathan Shaw, Group
Finance Director
Nominated Adviser &
Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Financial Public Relations
IFC Advisory Ltd 0203 053 8671
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's ODM is the only technology to
measure continuously blood flow in the central circulation in real
time. Minimally invasive, easy to set up and quick to focus, the
technology generates a low-frequency ultrasound signal, which is
highly sensitive to changes in flow and measures them immediately.
Deltex has been the only company in the enhanced haemodynamic space
to build a robust and credible evidence base proving the clinical
and economic benefits of its core technology, ODM. Randomised,
controlled trials using Doppler have demonstrated that early fluid
management intervention will reduce post-operative complications,
reduce intensive care admissions, and reduce the length of hospital
stay.
Company goal
ODM is increasingly recognised as a standard of care for
patients undergoing major surgery and in critical care. The broader
clinical area of haemodynamic management of which ODM is a core
constituent is also now becoming widely accepted as an important
major new medical modality. Consequently, the Company's focus is on
maximising value from the opportunities presented as enhanced
haemodynamic management is adopted into routine clinical practice
around the world.
The Company is currently in the implementation phase of
achieving this goal in a number of territories worldwide, operating
directly in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the
world and around 700,000 patients have been treated to date using
Deltex Medical's single patient disposable probes.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEDMGGDGDKGNZM
(END) Dow Jones Newswires
April 04, 2017 06:51 ET (10:51 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024